Featured Research

from universities, journals, and other organizations

Timing of first menstual cycle may be predictor of cardiovascular disease risk in women

Date:
November 14, 2012
Source:
Endocrine Society
Summary:
Age at onset of menarche (first menstrual cycle) is associated with increased body mass index (BMI), waist circumference, and overall obesity in adulthood, according to a recent study.

Age at onset of menarche (first menstrual cycle) is associated with increased body mass index (BMI), waist circumference, and overall obesity in adulthood, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

Cardiovascular disease (CVD) is the leading cause of death in women in the United States. When compared to men, women may manifest their clinical disease later in life, rendering standard risk prediction algorithms less reliable in women. The current study uses a life course approach, which looks for associations between earlier life events and later health outcomes, to better understand and predict CVD risk in women at their pre-clinical stage.

"The purpose of this study was to examine whether female reproductive risk factors -- including onset of menarche, number of births over a lifetime (called parity), onset of menopause, and menopausal status -- are associated with indices of body fat composition," said Caroline S. Fox, MD, MPH, of the National Heart, Lung, and Blood Institute, and senior author of the study. "We found that earlier onset of menarche is associated with overall adiposity, whereas parity and menopausal age were not associated with adiposity measures. Post-menopausal women also had higher levels of overall adiposity, though this appeared to be mostly due to age and not menopausal status."

The study featured 1,638 women who participated in the Framingham Heart Study (FHS) between 2002 and 2005. These participants were aged 40 or older, weighed less than 160 kg and not pregnant. Study participants underwent a physical exam along with laboratory analyses to measure visceral adiposity (VAT, the "belly fat" around the abdomen) and subcutaneous adiposity (SAT, the fat under the skin). The study modeled the relationship between VAT, SAT, and female reproductive factors after adjusting for age, smoking status, alcohol intake, physical activity index, hormone replacement therapy and menopausal status. Results of the study showed the timing of the first menstrual cycle was associated with generalized but not regional body fat depots.

"This research suggests that select female reproductive risk factors, specifically onset of menarche, are associated with overall adiposity, but not with specific indices of body fat distribution," said Dr. Subbulaxmi Trikudanathan, of Harvard Medical School in Boston, MA, and lead author of the study . "Ultimately, the important question is whether female reproductive risk factors can be used to target lifestyle interventions in high risk women to prevent the metabolic consequences of obesity and cardiovascular disease."

Other researchers working on the study include: Udo Hoffmann, and Ellen W. Seely of Harvard Medical School, Boston, Massachusetts; Alison Pedley of the National Institutes of Health, Bethesda, Maryland; and Joseph M. Massaro and Joanne M. Murabito of Boston University.

The article, "Association of female reproductive factors with body composition: the Framingham Heart Study," appears in the January 2013 issue of JCEM.


Story Source:

The above story is based on materials provided by Endocrine Society. Note: Materials may be edited for content and length.


Journal Reference:

  1. S. Trikudanathan, A. Pedley, J. M. Massaro, U. Hoffmann, E. W. Seely, J. M. Murabito, C. S. Fox. Association of Female Reproductive Factors with Body Composition: The Framingham Heart Study. Journal of Clinical Endocrinology & Metabolism, 2012; DOI: 10.1210/jc.2012-1785

Cite This Page:

Endocrine Society. "Timing of first menstual cycle may be predictor of cardiovascular disease risk in women." ScienceDaily. ScienceDaily, 14 November 2012. <www.sciencedaily.com/releases/2012/11/121114083222.htm>.
Endocrine Society. (2012, November 14). Timing of first menstual cycle may be predictor of cardiovascular disease risk in women. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2012/11/121114083222.htm
Endocrine Society. "Timing of first menstual cycle may be predictor of cardiovascular disease risk in women." ScienceDaily. www.sciencedaily.com/releases/2012/11/121114083222.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins